P122 High correlation between faecal calprotectin and a Novel Integral Index for evaluating disease activity in ulcerative colitis patients
ECCO'20 Vienna
2020
P123 Sarcopenia is a predictor for severe disease course in paediatric inflammatory bowel disease
ECCO'20 Vienna
2020
P124 Clock gene expression levels can differentially distinguish between ulcerative colitis and Crohn’s disease
ECCO'20 Vienna
2020
P125 Histological activity as a predictor of clinical outcome in ulcerative colitis: a 1-year prospective study
ECCO'20 Vienna
2020
P126 The Urgency Numeric Rating Scale (NRS): a novel patient-reported outcome measure to assess bowel urgency in adult patients with ulcerative colitis
ECCO'20 Vienna
2020
P127 Lemann Index for Assessment of Crohn’s disease association with the quality of life, endoscopic disease activity and magnetic resonance indices of activity
ECCO'20 Vienna
2020
P128 Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real life experience
ECCO'20 Vienna
2020
P129 Value of diffusion-weighted magnetic resonance enterocolonography for assessing Crohn’s disease activity
ECCO'20 Vienna
2020
P130 Faecal calprotectin is a reliable tool to assess endoscopic activity in ulcerative colitis except for short-extent proctitis
ECCO'20 Vienna
2020
P132 Performance of a severity score in risk stratification of patients with ulcerative colitis
ECCO'20 Vienna
2020
P134 Patient empowerment in inflammatory bowel disease (IBD): early education at a new diagnosis IBD clinic (NDC)
ECCO'20 Vienna
2020
P135 Disease-related worries and concerns in UK patients with ulcerative colitis: 2-year data from ICONIC
ECCO'20 Vienna
2020
P136 Faecal calprotectin as therapeutic target in patients with Crohn’s disease treated with anti-TNF: a meta-analysis of individual data
ECCO'20 Vienna
2020
P137 Is there an abuse in the histological diagnosis of Crohn’s disease? (retrospective study)
ECCO'20 Vienna
2020
P139 Prevalence of infections in patients affected by inflammatory bowel disease treated with anti-TNF-α agents: a single-centre experience
ECCO'20 Vienna
2020